

OncoTherapy Science, Inc.

November 13, 2014

A press release from Kumamoto University regarding a clinical study using
three cancer-specific peptide vaccines

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, “OncoTherapy”) announces that Kumamoto University has issued a press release on a clinical study (investigator-initiated phase II clinical trial) using three cancer-specific peptide vaccines whose intellectual property rights are owned by OncoTherapy and were exclusively licensed to a pharmaceutical company.

Dr. Masanori Shinohara, a former professor (currently Professor Emeritus) at Department of Oral and Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, and colleagues, in a collaborative with Professor Yasuharu Nishimura at Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, and Professor Yusuke Nakamura at Department of Medicine, The University of Chicago and others, applied the vaccine therapy using the three cancer-specific antigen peptides to patients with advanced head and neck cancers for whom no treatment option was available. The vaccines significantly enhanced the immune response of cytotoxic T lymphocytes (CTLs) that have ability to kill cancer cells, and successfully prolonged the survival of the patients, particularly those in whom CTLs against all of the three cancer-specific antigen peptides were induced

A paper describing the results from this clinical study has been published in *Clinical Cancer Research*, an academic journal published by the American Association for Cancer Research, and is available from the following Web site:

<http://clincancerres.aacrjournals.org/content/early/2014/11/12/1078-0432.CCR-14-0202.abstract>

The combination of vaccines used in this clinical study was different from the vaccines previously tested in the clinical trials led by OncoTherapy. All of the three peptides were developed from the oncoantigens that were previously discovered in the laboratory of Professor Yusuke Nakamura at The Institute of Medical Science, The University of Tokyo.

OncoTherapy considers that the results shown in this clinical study suggest the future direction of cancer vaccine development, a combination of multiple cancer-specific antigen peptides.